NeuBase Reports Business Update and Financial Results for the First Quarter of 2023
May 11, 2023 16:15 ET
|
NeuBase Therapeutics, Inc.
Announced oral presentations at the American Society of Gene & Cell Therapy (“ASGCT”) 26th Annual Meeting to take place on May 16-20, 2023 Company to present additional data showcasing gene...
NeuBase Therapeutics Selected to Present Two Oral Presentations at the American Society of Gene & Cell Therapy (ASGCT) 2023 Annual Meeting
May 02, 2023 17:00 ET
|
NeuBase Therapeutics, Inc.
PITTSBURGH, May 02, 2023 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology company developing Stealth Editors™ to perform in vivo gene...
NeuBase Therapeutics Reports Business Update and Financial Results for the First Quarter of Fiscal Year 2023
February 14, 2023 16:10 ET
|
NeuBase Therapeutics, Inc.
PITTSBURGH, Feb. 14, 2023 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the...
NeuBase Therapeutics Reports Business Update and Financial Results for Fiscal Year 2022
December 21, 2022 08:00 ET
|
NeuBase Therapeutics, Inc.
PITTSBURGH, Dec. 21, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the...
NeuBase Therapeutics Announces Gene Editing Research Agreement with Global Healthcare Company
October 21, 2022 08:00 ET
|
NeuBase Therapeutics, Inc.
PITTSBURGH, Oct. 21, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the...
NeuBase Therapeutics Announces Strategic Restructuring Focused on Advancing Its Platform in Gene Editing
October 14, 2022 16:05 ET
|
NeuBase Therapeutics, Inc.
Workforce reductions of ~60% and implementation of a robust cost reduction plan are expected to extend the Company’s cash runway into Q2 CY2024The Company plans to maximize shareholder value by...
NeuBase to Participate at Chardan’s 6th Annual Genetic Medicines Conference
September 22, 2022 16:05 ET
|
NeuBase Therapeutics, Inc.
PITTSBURGH and CAMBRIDGE, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to...
NeuBase Therapeutics Reports Business Update and Financial Results for the Third Quarter of Fiscal Year 2022
August 11, 2022 08:00 ET
|
NeuBase Therapeutics, Inc.
Lead myotonic dystrophy type 1 (DM1) candidate continues to show promising preclinical data, including the pharmacokinetics (PK) and biodistribution data presented at the American Society of Gene and...
NeuBase Therapeutics Announces Promotion of Dr. William Mann to President and COO
June 29, 2022 08:01 ET
|
NeuBase Therapeutics, Inc.
PITTSBURGH and CAMBRIDGE, Mass., June 29, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to...
NeuBase to Participate at the Jefferies Healthcare Conference
June 01, 2022 07:00 ET
|
NeuBase Therapeutics, Inc.
PITTSBURGH and CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology platform company Drugging the Genome™ to...